TY - JOUR
T1 - Prevention and management of chronic kidney disease in type 2 diabetes
AU - Chadban, S.
AU - Howell, M.
AU - Twigg, S.
AU - Thomas, M.
AU - Jerums, George
AU - Cass, A.
AU - Campbell, D.
AU - Nicholls, K.
AU - Tong, A.
AU - Mangos, G.
AU - Stack, A.
AU - MacIsaac, R. J.
AU - Girgis, S.
AU - Colagiuri, R.
AU - Colagiuri, S.
AU - Craig, J.
PY - 2010/4/1
Y1 - 2010/4/1
N2 - This guideline topic has been taken from the NHMRC ‘National Evidence Based Guidelines for Diagnosis, Prevention and Management of CKD in Type 2 Diabetes’ which can be found in full at the CARI website (http://www.cari.org.au). The NHMRC guideline covers issues related to the assessment and prevention of CKD in individuals with established type 2 diabetes. The NHMRC guidelines do not address the care of people with diabetes who have end‐stage kidney disease or those who have a functional renal transplant. In addition, the present guideline does not provide recommendations regarding the management of individuals with established CKD, with respect to the prevention of other (non‐renal) adverse outcomes, including retinopathy, hypoglycaemia, bone disease and cardiovascular disease. It is important to note however, that in an individual with type 2 diabetes, the prevention of these complications may be a more important determinant for their clinical care. Consequently, the recommendations made must be balanced against the overall management needs of each individual patient.
AB - This guideline topic has been taken from the NHMRC ‘National Evidence Based Guidelines for Diagnosis, Prevention and Management of CKD in Type 2 Diabetes’ which can be found in full at the CARI website (http://www.cari.org.au). The NHMRC guideline covers issues related to the assessment and prevention of CKD in individuals with established type 2 diabetes. The NHMRC guidelines do not address the care of people with diabetes who have end‐stage kidney disease or those who have a functional renal transplant. In addition, the present guideline does not provide recommendations regarding the management of individuals with established CKD, with respect to the prevention of other (non‐renal) adverse outcomes, including retinopathy, hypoglycaemia, bone disease and cardiovascular disease. It is important to note however, that in an individual with type 2 diabetes, the prevention of these complications may be a more important determinant for their clinical care. Consequently, the recommendations made must be balanced against the overall management needs of each individual patient.
UR - http://www.scopus.com/inward/record.url?scp=77950475233&partnerID=8YFLogxK
U2 - 10.1111/j.1440-1797.2010.01240.x
DO - 10.1111/j.1440-1797.2010.01240.x
M3 - Article
C2 - 20591029
AN - SCOPUS:77950475233
VL - 15
SP - S162-S194
JO - Nephrology
JF - Nephrology
SN - 1320-5358
IS - Supp. 1
ER -